Details of the Drug

General Information of Drug (ID: DM5SYZP)

Drug Name
Disopyramide
Synonyms
Dicorantil; Disopiramida; Disopyramidum; Isorythm; Lispine; Ritmodan; Rythmodan; Disopyramide Free Base; Rythmodan P; D 7644; H 3292; SC 7031; Searle 703; Disopiramida [INN-Spanish]; Disopyramidum [INN-Latin]; Norpace (TN); Rythmodan (TN); Rythmodan P (TN); Rythmodan-La; SC-7031; Xi-Disopyramide; Disopyramide (JP15/USAN/INN); Disopyramide [USAN:BAN:INN:JAN]; Alpha-Diisopropylaminoethyl-alpha-phenylpyridine-2-acetamide; Gamma-Diisopropylamino-alpha-phenyl-alpha-(2-pyridyl)butyramide; Alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide; Alpha-[2-[Bis(1-methylethyl)amino]ethyl]-alpha-phenyl-2-pyridine acetamide; 4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide; 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
Indication
Disease Entry ICD 11 Status REF
Ventricular arrhythmias BC71 Approved [1], [2]
Urinary incontinence MF50.2 Withdrawn from market [1], [3]
Therapeutic Class
Antiarrhythmic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 339.5
Topological Polar Surface Area (xlogp) 3.2
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Bioavailability
The bioavailability of drug is 100% [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.9 mL/min/kg [6]
Elimination
55% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 6.7 (range 4 - 10) hours [6]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.89136 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.16% [6]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.52 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 1 mg/mL [4]
Chemical Identifiers
Formula
C21H29N3O
IUPAC Name
4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
Canonical SMILES
CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C
InChI
InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
InChIKey
UVTNFZQICZKOEM-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3114
ChEBI ID
CHEBI:4657
CAS Number
3737-09-5
DrugBank ID
DB00280
TTD ID
D0M4YC
VARIDT ID
DR00644
INTEDE ID
DR0518
ACDINA ID
D00205

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated sodium channel alpha Nav1.5 (SCN5A) TTZOVE0 SCN5A_HUMAN Blocker [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Disopyramide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Bretylium DM1FX74 Major Increased risk of prolong QT interval by the combination of Disopyramide and Bretylium. Ventricular tachyarrhythmia [BC71] [45]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Disopyramide and Procainamide. Ventricular tachyarrhythmia [BC71] [46]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Disopyramide and Propafenone. Ventricular tachyarrhythmia [BC71] [47]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Disopyramide and Flecainide. Ventricular tachyarrhythmia [BC71] [46]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Disopyramide and Amiodarone. Ventricular tachyarrhythmia [BC71] [48]
Coadministration of a Drug Treating the Disease Different from Disopyramide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bethanechol DMCLHO0 Moderate Antagonize the effect of Disopyramide when combined with Bethanechol. Abnormal micturition [MF50] [49]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Disopyramide and Repaglinide. Acute diabete complication [5A2Y] [50]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Disopyramide and Glibenclamide. Acute diabete complication [5A2Y] [50]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Disopyramide and Tolazamide. Acute diabete complication [5A2Y] [50]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Disopyramide and Nateglinide. Acute diabete complication [5A2Y] [50]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Disopyramide and Insulin-glulisine. Acute diabete complication [5A2Y] [50]
Acetohexamide DMR6N7H Moderate Increased risk of hypoglycemia by the combination of Disopyramide and Acetohexamide. Acute diabete complication [5A2Y] [50]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Disopyramide and Insulin-aspart. Acute diabete complication [5A2Y] [51]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Disopyramide and Glipizide. Acute diabete complication [5A2Y] [50]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Disopyramide and Ivosidenib. Acute myeloid leukaemia [2A60] [46]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Disopyramide and Midostaurin. Acute myeloid leukaemia [2A60] [46]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Disopyramide and Idarubicin. Acute myeloid leukaemia [2A60] [46]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Disopyramide and Daunorubicin. Acute myeloid leukaemia [2A60] [46]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Disopyramide and Arn-509. Acute myeloid leukaemia [2A60] [46]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Disopyramide and Gilteritinib. Acute myeloid leukaemia [2A60] [46]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Disopyramide and Oliceridine. Acute pain [MG31] [46]
Emapalumab DMZG5WL Moderate Altered metabolism of Disopyramide due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [52]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Disopyramide and Scopolamine. Addictive disorder [6C50-6C5Z] [53]
Terfenadine DM4KLPT Major Increased risk of prolong QT interval by the combination of Disopyramide and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [46]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Disopyramide and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [54]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Disopyramide and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [54]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Disopyramide and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [53]
Tacrine DM51FY6 Moderate Antagonize the effect of Disopyramide when combined with Tacrine. Alzheimer disease [8A20] [55]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Disopyramide and Memantine. Alzheimer disease [8A20] [53]
Galantamine DMEO794 Moderate Antagonize the effect of Disopyramide when combined with Galantamine. Alzheimer disease [8A20] [55]
Rivastigmine DMG629M Moderate Antagonize the effect of Disopyramide when combined with Rivastigmine. Alzheimer disease [8A20] [55]
Donepezil DMIYG7Z Moderate Antagonize the effect of Disopyramide when combined with Donepezil. Alzheimer disease [8A20] [55]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Disopyramide and Metronidazole. Amoebiasis [1A36] [45]
Siltuximab DMGEATB Moderate Altered metabolism of Disopyramide due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [52]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Disopyramide and Ivabradine. Angina pectoris [BA40] [52]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Disopyramide and Bepridil. Angina pectoris [BA40] [56]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Disopyramide and Dronedarone. Angina pectoris [BA40] [46]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Disopyramide and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [46]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Disopyramide caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [57]
Hydroxyzine DMF8Y74 Major Increased risk of prolong QT interval by the combination of Disopyramide and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [46]
Promazine DMZAL7W Major Increased risk of prolong QT interval by the combination of Disopyramide and Promazine. Appearance/behaviour symptom [MB23] [46]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Disopyramide and Cilostazol. Arterial occlusive disease [BD40] [46]
Voriconazole DMAOL2S Major Increased risk of prolong QT interval by the combination of Disopyramide and Voriconazole. Aspergillosis [1F20] [46]
Posaconazole DMUL5EW Major Decreased metabolism of Disopyramide caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [58]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Disopyramide and Levalbuterol. Asthma [CA23] [59]
Terbutaline DMD4381 Major Increased risk of prolong QT interval by the combination of Disopyramide and Terbutaline. Asthma [CA23] [60]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Pirbuterol. Asthma [CA23] [60]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Salbutamol. Asthma [CA23] [61]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Disopyramide and Formoterol. Asthma [CA23] [60]
Atomoxetine DM5L6HI Major Increased risk of prolong QT interval by the combination of Disopyramide and Atomoxetine. Attention deficit hyperactivity disorder [6A05] [46]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Disopyramide and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [46]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Disopyramide and Desipramine. Attention deficit hyperactivity disorder [6A05] [46]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Disopyramide and Ofloxacin. Bacterial infection [1A00-1C4Z] [62]
Ciprofloxacin XR DM2NLS9 Major Increased risk of prolong QT interval by the combination of Disopyramide and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [62]
Dalfopristin DM4LTKV Major Decreased metabolism of Disopyramide caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [63]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Disopyramide and Clarithromycin. Bacterial infection [1A00-1C4Z] [45]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Disopyramide and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [46]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Disopyramide and Sparfloxacin. Bacterial infection [1A00-1C4Z] [62]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Disopyramide and Gemifloxacin. Bacterial infection [1A00-1C4Z] [62]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Disopyramide and Norfloxacin. Bacterial infection [1A00-1C4Z] [62]
Capreomycin DMNZBRY Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Capreomycin. Bacterial infection [1A00-1C4Z] [52]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Disopyramide and Levofloxacin. Bacterial infection [1A00-1C4Z] [62]
Troleandomycin DMUZNIG Major Increased risk of prolong QT interval by the combination of Disopyramide and Troleandomycin. Bacterial infection [1A00-1C4Z] [45]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Disopyramide and Lomefloxacin. Bacterial infection [1A00-1C4Z] [62]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Disopyramide and Telithromycin. Bacterial infection [1A00-1C4Z] [64]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Disopyramide and Retigabine. Behcet disease [4A62] [46]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Disopyramide and Cariprazine. Bipolar disorder [6A60] [53]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Disopyramide and Loperamide. Bowel habit change [ME05] [65]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Disopyramide and Eribulin. Breast cancer [2C60-2C6Y] [46]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Disopyramide and Lapatinib. Breast cancer [2C60-2C6Y] [46]
Tucatinib DMBESUA Major Decreased metabolism of Disopyramide caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [58]
Tamoxifen DMLB0EZ Major Increased risk of prolong QT interval by the combination of Disopyramide and Tamoxifen. Breast cancer [2C60-2C6Y] [46]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Disopyramide and Toremifene. Breast cancer [2C60-2C6Y] [46]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Disopyramide and Bosutinib. Breast cancer [2C60-2C6Y] [46]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Disopyramide and Grepafloxacin. Bronchitis [CA20] [66]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Disopyramide and Sotalol. Cardiac arrhythmia [BC9Z] [46]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Disopyramide when combined with Acetylcholine. Cataract [9B10] [67]
Iodipamide DMXIQYS Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Iodipamide. Cholelithiasis [DC11] [68]
Secobarbital DM14RF5 Moderate Increased metabolism of Disopyramide caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [69]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Disopyramide and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [46]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Disopyramide and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [70]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Olodaterol. Chronic obstructive pulmonary disease [CA22] [60]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Disopyramide and Vilanterol. Chronic obstructive pulmonary disease [CA22] [59]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Disopyramide and Tiotropium. Chronic obstructive pulmonary disease [CA22] [70]
Ipratropium DMFQ320 Moderate Additive anticholinergic effects by the combination of Disopyramide and Ipratropium. Chronic obstructive pulmonary disease [CA22] [70]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Salmeterol. Chronic obstructive pulmonary disease [CA22] [60]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Disopyramide and Revefenacin. Chronic obstructive pulmonary disease [CA22] [70]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Indacaterol. Chronic obstructive pulmonary disease [CA22] [60]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Disopyramide and Arformoterol. Chronic obstructive pulmonary disease [CA22] [60]
Oxaliplatin DMQNWRD Major Increased risk of prolong QT interval by the combination of Disopyramide and Oxaliplatin. Colorectal cancer [2B91] [46]
Panitumumab DMQPD1F Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Panitumumab. Colorectal cancer [2B91] [52]
Isoproterenol DMK7MEY Major Increased risk of prolong QT interval by the combination of Disopyramide and Isoproterenol. Conduction disorder [BC63] [60]
Methohexital DM7YMIT Moderate Increased metabolism of Disopyramide caused by Methohexital mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [69]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Disopyramide and Halothane. Corneal disease [9A76-9A78] [46]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Disopyramide and Propofol. Corneal disease [9A76-9A78] [71]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Disopyramide and Sevoflurane. Corneal disease [9A76-9A78] [46]
Thiopental DMGP8AX Moderate Increased metabolism of Disopyramide caused by Thiopental mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [69]
Lidocaine DML4ZOT Moderate Increased risk of cardiac depression by the combination of Disopyramide and Lidocaine. Corneal disease [9A76-9A78] [72]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Disopyramide and Probucol. Coronary atherosclerosis [BA80] [46]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Disopyramide and Methadone. Cough [MD12] [46]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Disopyramide and Clofazimine. Crohn disease [DD70] [46]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Disopyramide and Mifepristone. Cushing syndrome [5A70] [46]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Disopyramide and Pasireotide. Cushing syndrome [5A70] [46]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Disopyramide and Osilodrostat. Cushing syndrome [5A70] [46]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Disopyramide caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [73]
Ethanol DMDRQZU Minor Increased renal excretion of Disopyramide caused by Ethanol. Cystitis [GC00] [74]
MK-8228 DMOB58Q Moderate Decreased metabolism of Disopyramide caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [75]
Aprepitant DM053KT Moderate Decreased metabolism of Disopyramide caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [76]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Disopyramide and Sertraline. Depression [6A70-6A7Z] [46]
Trimipramine DM1SC8M Major Increased risk of prolong QT interval by the combination of Disopyramide and Trimipramine. Depression [6A70-6A7Z] [46]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Disopyramide and Cyclobenzaprine. Depression [6A70-6A7Z] [53]
Imipramine DM2NUH3 Major Increased risk of prolong QT interval by the combination of Disopyramide and Imipramine. Depression [6A70-6A7Z] [46]
Fluoxetine DM3PD2C Major Increased risk of prolong QT interval by the combination of Disopyramide and Fluoxetine. Depression [6A70-6A7Z] [46]
Nortriptyline DM4KDYJ Major Increased risk of prolong QT interval by the combination of Disopyramide and Nortriptyline. Depression [6A70-6A7Z] [46]
Nefazodone DM4ZS8M Major Decreased metabolism of Disopyramide caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [58]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Disopyramide and Escitalopram. Depression [6A70-6A7Z] [46]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Disopyramide and OPC-34712. Depression [6A70-6A7Z] [53]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Disopyramide and Clomipramine. Depression [6A70-6A7Z] [46]
Trazodone DMK1GBJ Major Increased risk of prolong QT interval by the combination of Disopyramide and Trazodone. Depression [6A70-6A7Z] [46]
Amoxapine DMKITQE Major Increased risk of prolong QT interval by the combination of Disopyramide and Amoxapine. Depression [6A70-6A7Z] [46]
Mirtazapine DML53ZJ Major Increased risk of prolong QT interval by the combination of Disopyramide and Mirtazapine. Depression [6A70-6A7Z] [46]
Protriptyline DMNHTZI Major Increased risk of prolong QT interval by the combination of Disopyramide and Protriptyline. Depression [6A70-6A7Z] [46]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Disopyramide and Doxepin. Depression [6A70-6A7Z] [46]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Disopyramide and Maprotiline. Depression [6A70-6A7Z] [46]
Venlafaxine DMR6QH0 Major Increased risk of prolong QT interval by the combination of Disopyramide and Venlafaxine. Depression [6A70-6A7Z] [46]
Hyoscyamine DM804UR Moderate Additive anticholinergic effects by the combination of Disopyramide and Hyoscyamine. Digestive system disease [DE2Z] [53]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Disopyramide and Mepenzolate. Digestive system disease [DE2Z] [53]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Disopyramide and Oxybutynine. Discovery agent [N.A.] [53]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Disopyramide and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [46]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Disopyramide and Meclizine. Dizziness and giddiness [MB48] [53]
Trihexyphenidyl DMB19L8 Moderate Additive anticholinergic effects by the combination of Disopyramide and Trihexyphenidyl. Dystonic disorder [8A02] [53]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Disopyramide and Deutetrabenazine. Dystonic disorder [8A02] [46]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Disopyramide and Ingrezza. Dystonic disorder [8A02] [46]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Disopyramide and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [77]
Primidone DM0WX6I Moderate Increased metabolism of Disopyramide caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [69]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Disopyramide caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [78]
Mephenytoin DM5UGDK Moderate Increased metabolism of Disopyramide caused by Mephenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [79]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Disopyramide caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [79]
Rufinamide DMWE60C Moderate Increased metabolism of Disopyramide caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [52]
Phenobarbital DMXZOCG Moderate Increased metabolism of Disopyramide caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [69]
Timolol DM3NXRU Major Additive hypotensive effects by the combination of Disopyramide and Timolol. Essential hypertension [BA00] [80]
Ethacrynic acid DM60QMR Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Ethacrynic acid. Essential hypertension [BA00] [52]
Bendroflumethiazide DM7EVLC Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Bendroflumethiazide. Essential hypertension [BA00] [52]
Benzthiazide DMQWZ0H Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Benzthiazide. Essential hypertension [BA00] [52]
Nadolol DMW6GVL Major Increased risk of bradycardia by the combination of Disopyramide and Nadolol. Essential hypertension [BA00] [80]
Tazemetostat DMWP1BH Moderate Increased metabolism of Disopyramide caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [81]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Disopyramide and Solifenacin. Functional bladder disorder [GC50] [46]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Disopyramide and Tolterodine. Functional bladder disorder [GC50] [53]
Darifenacin DMWXLYZ Moderate Additive anticholinergic effects by the combination of Disopyramide and Darifenacin. Functional bladder disorder [GC50] [53]
Itraconazole DMCR1MV Major Decreased metabolism of Disopyramide caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [46]
Pentamidine DMHZJCG Major Increased risk of prolong QT interval by the combination of Disopyramide and Pentamidine. Fungal infection [1F29-1F2F] [46]
Miconazole DMPMYE8 Moderate Decreased metabolism of Disopyramide caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [82]
Ketoconazole DMPZI3Q Major Decreased metabolism of Disopyramide caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [83]
Amphotericin B DMTAJQE Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Amphotericin B. Fungal infection [1F29-1F2F] [52]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Disopyramide and Propantheline. Gastric ulcer [DA60] [53]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Disopyramide and Cisapride. Gastro-oesophageal reflux disease [DA22] [46]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Disopyramide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [46]
Acetazolamide DM1AF5U Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Acetazolamide. Glaucoma [9C61] [52]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Disopyramide when combined with Isoflurophate. Glaucoma [9C61] [67]
Carteolol DMFMDOB Major Increased risk of bradycardia by the combination of Disopyramide and Carteolol. Glaucoma [9C61] [80]
Metipranolol DMJMVKI Moderate Increased risk of prolong QT interval by the combination of Disopyramide and Metipranolol. Glaucoma [9C61] [80]
Levobetaxolol DMSREPX Moderate Increased risk of prolong QT interval by the combination of Disopyramide and Levobetaxolol. Glaucoma [9C61] [80]
Levobunolol DMTNFCQ Moderate Increased risk of hypoglycemia by the combination of Disopyramide and Levobunolol. Glaucoma [9C61] [80]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Disopyramide when combined with Pilocarpine. Glaucoma [9C61] [49]
Carvedilol DMHTEAO Major Increased risk of prolong QT interval by the combination of Disopyramide and Carvedilol. Heart failure [BD10-BD1Z] [80]
Chlorothiazide DMLHESP Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Chlorothiazide. Heart failure [BD10-BD1Z] [52]
Furosemide DMMQ8ZG Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Furosemide. Heart failure [BD10-BD1Z] [52]
Bumetanide DMRV7H0 Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Bumetanide. Heart failure [BD10-BD1Z] [52]
Hydroflumethiazide DMVPUQI Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Hydroflumethiazide. Heart failure [BD10-BD1Z] [52]
Boceprevir DMBSHMF Major Decreased metabolism of Disopyramide caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [84]
Simeprevir DMLUA9D Moderate Decreased metabolism of Disopyramide caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [85]
Telaprevir DMMRV29 Major Decreased metabolism of Disopyramide caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [52]
Rifampin DMA8J1G Moderate Increased metabolism of Disopyramide caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [86]
Rifapentine DMCHV4I Moderate Increased metabolism of Disopyramide caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [87]
Delavirdine DM3NF5G Major Decreased metabolism of Disopyramide caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [58]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Disopyramide caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Disopyramide and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [46]
Cobicistat DM6L4H2 Major Decreased metabolism of Disopyramide caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [89]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Disopyramide and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [46]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Disopyramide and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [90]
Etravirine DMGV8QU Moderate Increased metabolism of Disopyramide caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [91]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Disopyramide and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [46]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Disopyramide caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Darunavir DMN3GCH Moderate Decreased metabolism of Disopyramide caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [45]
Atazanavir DMSYRBX Major Decreased metabolism of Disopyramide caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [58]
Ritonavir DMU764S Major Decreased metabolism of Disopyramide caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [58]
Acebutolol DM0TI4U Major Additive hypotensive effects by the combination of Disopyramide and Acebutolol. Hypertension [BA00-BA04] [80]
Bisoprolol DM3UZ95 Major Increased risk of hypoglycemia by the combination of Disopyramide and Bisoprolol. Hypertension [BA00-BA04] [80]
Penbutolol DM4ES8F Major Increased risk of hypoglycemia by the combination of Disopyramide and Penbutolol. Hypertension [BA00-BA04] [80]
Nebivolol DM7F1PA Major Increased risk of prolong QT interval by the combination of Disopyramide and Nebivolol. Hypertension [BA00-BA04] [80]
Diltiazem DMAI7ZV Moderate Decreased metabolism of Disopyramide caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [92]
Pindolol DMD2NV7 Major Increased risk of prolong QT interval by the combination of Disopyramide and Pindolol. Hypertension [BA00-BA04] [80]
Indapamide DMGN1PW Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Indapamide. Hypertension [BA00-BA04] [52]
Labetalol DMK8U72 Major Additive hypotensive effects by the combination of Disopyramide and Labetalol. Hypertension [BA00-BA04] [80]
Atenolol DMNKG1Z Major Increased risk of bradycardia by the combination of Disopyramide and Atenolol. Hypertension [BA00-BA04] [80]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Hydrochlorothiazide. Hypertension [BA00-BA04] [52]
Potassium chloride DMMTAJC Major Increased risk of GI mucosal injury/bleeding risk by the combination of Disopyramide and Potassium chloride. Hypo-kalaemia [5C77] [93]
Conivaptan DM1V329 Major Decreased metabolism of Disopyramide caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [94]
Fludrocortisone DMUDIR8 Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [52]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Disopyramide and Belladonna. Infectious gastroenteritis/colitis [1A40] [53]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Disopyramide and Amantadine. Influenza [1E30-1E32] [95]
Amobarbital DM0GQ8N Moderate Increased metabolism of Disopyramide caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [69]
Pentobarbital DMFNH7L Moderate Increased metabolism of Disopyramide caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [69]
Propiomazine DMKY8V1 Moderate Additive anticholinergic effects by the combination of Disopyramide and Propiomazine. Insomnia [7A00-7A0Z] [53]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Disopyramide and ITI-007. Insomnia [7A00-7A0Z] [53]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Disopyramide and Polyethylene glycol. Irritable bowel syndrome [DD91] [96]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Phenolphthalein. Irritable bowel syndrome [DD91] [46]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Disopyramide and Clidinium. Irritable bowel syndrome [DD91] [53]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Disopyramide and Dicyclomine. Irritable bowel syndrome [DD91] [53]
Physostigmine DM2N0TO Moderate Antagonize the effect of Disopyramide when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [55]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Disopyramide and Crizotinib. Lung cancer [2C25] [46]
Brigatinib DM7W94S Moderate Increased metabolism of Disopyramide caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [97]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Disopyramide and Ceritinib. Lung cancer [2C25] [46]
PF-06463922 DMKM7EW Moderate Increased metabolism of Disopyramide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [98]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Disopyramide and Osimertinib. Lung cancer [2C25] [46]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Disopyramide and Selpercatinib. Lung cancer [2C25] [46]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Disopyramide and Lumefantrine. Malaria [1F40-1F45] [45]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Disopyramide and Halofantrine. Malaria [1F40-1F45] [99]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Disopyramide and Chloroquine. Malaria [1F40-1F45] [46]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Disopyramide and Hydroxychloroquine. Malaria [1F40-1F45] [46]
Quinine DMSWYF5 Major Increased risk of prolong QT interval by the combination of Disopyramide and Quinine. Malaria [1F40-1F45] [46]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Disopyramide and Primaquine. Malaria [1F40-1F45] [46]
Mefloquine DMWT905 Major Increased risk of prolong QT interval by the combination of Disopyramide and Mefloquine. Malaria [1F40-1F45] [46]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Disopyramide and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [46]
Idelalisib DM602WT Major Decreased metabolism of Disopyramide caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [58]
IPI-145 DMWA24P Moderate Decreased metabolism of Disopyramide caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [100]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Disopyramide and Arsenic trioxide. Mature B-cell lymphoma [2A85] [101]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Disopyramide caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [102]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Disopyramide and Vemurafenib. Melanoma [2C30] [46]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Disopyramide and LGX818. Melanoma [2C30] [46]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Disopyramide caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [52]
Propranolol DM79NTF Major Increased risk of bradycardia by the combination of Disopyramide and Propranolol. Migraine [8A80] [80]
Exjade DMHPRWG Moderate Decreased metabolism of Disopyramide caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [103]
Doxylamine DMKOXFE Moderate Additive anticholinergic effects by the combination of Disopyramide and Doxylamine. Morning sickness disorder [SC00] [53]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Disopyramide and Panobinostat. Multiple myeloma [2A83] [46]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Disopyramide and Siponimod. Multiple sclerosis [8A40] [45]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Disopyramide and Ozanimod. Multiple sclerosis [8A40] [46]
Neostigmine DM6T2J3 Moderate Antagonize the effect of Disopyramide when combined with Neostigmine. Myasthenia gravis [8C6Y] [104]
Pyridostigmine DM8HO1L Moderate Antagonize the effect of Disopyramide when combined with Pyridostigmine. Myasthenia gravis [8C6Y] [104]
Edrophonium DMCRQHB Moderate Antagonize the effect of Disopyramide when combined with Edrophonium. Myasthenia gravis [8C6Y] [104]
Ambenonium DMOP0BL Moderate Antagonize the effect of Disopyramide when combined with Ambenonium. Myasthenia gravis [8C6Y] [104]
Rifabutin DM1YBHK Moderate Increased metabolism of Disopyramide caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [86]
Bexarotene DMOBIKY Moderate Increased metabolism of Disopyramide caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [52]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Disopyramide and Romidepsin. Mycosis fungoides [2B01] [46]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Disopyramide caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [52]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Disopyramide and Nilotinib. Myeloproliferative neoplasm [2A20] [46]
Imatinib DM7RJXL Moderate Decreased metabolism of Disopyramide caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [105]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Disopyramide and Dasatinib. Myeloproliferative neoplasm [2A20] [46]
Modafinil DMYILBE Minor Increased metabolism of Disopyramide caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [106]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Disopyramide and Phenindamine. Nasopharyngitis [CA00] [53]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Disopyramide and Droperidol. Nausea/vomiting [MD90] [46]
Dimenhydrinate DM264B3 Moderate Increased risk of prolong QT interval by the combination of Disopyramide and Dimenhydrinate. Nausea/vomiting [MD90] [45]
Prochlorperazine DM53SRA Major Increased risk of prolong QT interval by the combination of Disopyramide and Prochlorperazine. Nausea/vomiting [MD90] [46]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Disopyramide and Promethazine. Nausea/vomiting [MD90] [46]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Disopyramide and Cyclizine. Nausea/vomiting [MD90] [53]
Palonosetron DMBHMOX Major Increased risk of prolong QT interval by the combination of Disopyramide and Palonosetron. Nausea/vomiting [MD90] [46]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Disopyramide when combined with Metoclopramide. Nausea/vomiting [MD90] [107]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Disopyramide and Granisetron. Nausea/vomiting [MD90] [46]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Disopyramide and Dolasetron. Nausea/vomiting [MD90] [46]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Disopyramide and Ondansetron. Nausea/vomiting [MD90] [46]
Thiethylperazine DMU3IET Moderate Additive anticholinergic effects by the combination of Disopyramide and Thiethylperazine. Nausea/vomiting [MD90] [53]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Disopyramide and Entrectinib. Non-small cell lung cancer [2C25] [46]
Chlorthalidone DM4DMBT Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Chlorthalidone. Oedema [MG29] [52]
Metolazone DMB39LO Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Metolazone. Oedema [MG29] [52]
Polythiazide DMCH80F Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Polythiazide. Oedema [MG29] [52]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Disopyramide and Levomethadyl Acetate. Opioid use disorder [6C43] [52]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Disopyramide and Lofexidine. Opioid use disorder [6C43] [46]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Disopyramide and Rucaparib. Ovarian cancer [2C73] [46]
Dextropropoxyphene DM23HCX Major Increased risk of prolong QT interval by the combination of Disopyramide and Dextropropoxyphene. Pain [MG30-MG3Z] [46]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Disopyramide and Flavoxate. Pain [MG30-MG3Z] [53]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Disopyramide and Buprenorphine. Pain [MG30-MG3Z] [46]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Disopyramide and Triclabendazole. Parasitic worm infestation [1F90] [46]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Disopyramide and Biperiden. Parkinsonism [8A00] [53]
Procyclidine DMHFJDT Moderate Additive anticholinergic effects by the combination of Disopyramide and Procyclidine. Parkinsonism [8A00] [53]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Disopyramide and Pimavanserin. Parkinsonism [8A00] [46]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Disopyramide and Orphenadrine. Parkinsonism [8A00] [53]
Apomorphine DMX38HQ Major Increased risk of prolong QT interval by the combination of Disopyramide and Apomorphine. Parkinsonism [8A00] [46]
Abametapir DM2RX0I Moderate Decreased metabolism of Disopyramide caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [108]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Disopyramide and Methylscopolamine. Peptic ulcer [DA61] [53]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Disopyramide and Famotidine. Peptic ulcer [DA61] [45]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Disopyramide and Macimorelin. Pituitary gland disorder [5A60-5A61] [109]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Disopyramide and Lefamulin. Pneumonia [CA40] [110]
Prednisone DM2HG4X Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Prednisone. Postoperative inflammation [1A00-CA43] [52]
Betamethasone DMAHJEF Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Betamethasone. Postoperative inflammation [1A00-CA43] [52]
Hydrocortisone DMGEMB7 Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Hydrocortisone. Postoperative inflammation [1A00-CA43] [52]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Disopyramide caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [58]
Ritodrine DM4V6RL Major Increased risk of prolong QT interval by the combination of Disopyramide and Ritodrine. Preterm labour/delivery [JB00] [60]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Disopyramide and Degarelix. Prostate cancer [2C82] [46]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Disopyramide and ABIRATERONE. Prostate cancer [2C82] [46]
Nilutamide DMFN07X Major Increased risk of prolong QT interval by the combination of Disopyramide and Nilutamide. Prostate cancer [2C82] [46]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Disopyramide and Enzalutamide. Prostate cancer [2C82] [46]
Flutamide DMK0O7U Major Increased risk of prolong QT interval by the combination of Disopyramide and Flutamide. Prostate cancer [2C82] [46]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Disopyramide and Relugolix. Prostate cancer [2C82] [46]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Disopyramide and Bicalutamide. Prostate cancer [2C82] [46]
Alfuzosin DMZVMKF Major Increased risk of prolong QT interval by the combination of Disopyramide and Alfuzosin. Prostate hyperplasia [GA90] [46]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Disopyramide due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [52]
Ixekizumab DMXW92T Moderate Altered metabolism of Disopyramide due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [52]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Disopyramide and Levomepromazine. Psychotic disorder [6A20-6A25] [46]
Fluphenazine DMIT8LX Major Increased risk of prolong QT interval by the combination of Disopyramide and Fluphenazine. Psychotic disorder [6A20-6A25] [46]
Triflupromazine DMKFQJP Major Increased risk of prolong QT interval by the combination of Disopyramide and Triflupromazine. Psychotic disorder [6A20-6A25] [46]
Bosentan DMIOGBU Moderate Increased metabolism of Disopyramide caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [111]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Disopyramide and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [112]
Sorafenib DMS8IFC Major Increased risk of prolong QT interval by the combination of Disopyramide and Sorafenib. Renal cell carcinoma [2C90] [46]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Disopyramide and Gatifloxacin. Respiratory infection [CA07-CA4Z] [62]
Tocilizumab DM7J6OR Moderate Altered metabolism of Disopyramide due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [52]
Canakinumab DM8HLO5 Moderate Altered metabolism of Disopyramide due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [52]
Cyproheptadine DM92AH3 Moderate Additive anticholinergic effects by the combination of Disopyramide and Cyproheptadine. Rheumatoid arthritis [FA20] [53]
Rilonacept DMGLUQS Moderate Altered metabolism of Disopyramide due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [52]
Golimumab DMHZV7X Moderate Altered metabolism of Disopyramide due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [52]
Dexamethasone DMMWZET Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Dexamethasone. Rheumatoid arthritis [FA20] [52]
Sarilumab DMOGNXY Moderate Altered metabolism of Disopyramide due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [52]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Disopyramide and Quetiapine. Schizophrenia [6A20] [46]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Disopyramide and Mesoridazine. Schizophrenia [6A20] [46]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Disopyramide and Thioridazine. Schizophrenia [6A20] [46]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Disopyramide and Aripiprazole. Schizophrenia [6A20] [53]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Disopyramide and Iloperidone. Schizophrenia [6A20] [46]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Disopyramide and Paliperidone. Schizophrenia [6A20] [46]
Loxapine DM8AI9U Moderate Additive anticholinergic effects by the combination of Disopyramide and Loxapine. Schizophrenia [6A20] [53]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Disopyramide and Haloperidol. Schizophrenia [6A20] [46]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Disopyramide and Perphenazine. Schizophrenia [6A20] [46]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Disopyramide and Molindone. Schizophrenia [6A20] [53]
Chlorpromazine DMBGZI3 Major Increased risk of prolong QT interval by the combination of Disopyramide and Chlorpromazine. Schizophrenia [6A20] [46]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Disopyramide and Thiothixene. Schizophrenia [6A20] [53]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Disopyramide and Clozapine. Schizophrenia [6A20] [46]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Disopyramide and Trifluoperazine. Schizophrenia [6A20] [46]
Risperidone DMN6DXL Major Increased risk of prolong QT interval by the combination of Disopyramide and Risperidone. Schizophrenia [6A20] [46]
Olanzapine DMPFN6Y Moderate Additive anticholinergic effects by the combination of Disopyramide and Olanzapine. Schizophrenia [6A20] [53]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Disopyramide and Amisulpride. Schizophrenia [6A20] [46]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Disopyramide and Asenapine. Schizophrenia [6A20] [46]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Disopyramide and Pimozide. Schizophrenia [6A20] [52]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Disopyramide and Vardenafil. Sexual dysfunction [HA00-HA01] [113]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Disopyramide caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [52]
Larotrectinib DM26CQR Moderate Decreased metabolism of Disopyramide caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [45]
Methylprednisolone DM4BDON Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [52]
Armodafinil DMGB035 Minor Increased metabolism of Disopyramide caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [106]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Disopyramide and LEE011. Solid tumour/cancer [2A00-2F9Z] [46]
Epirubicin DMPDW6T Major Increased risk of prolong QT interval by the combination of Disopyramide and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [46]
Cisplatin DMRHGI9 Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Cisplatin. Solid tumour/cancer [2A00-2F9Z] [52]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Disopyramide and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [114]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Disopyramide and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [46]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Disopyramide and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [46]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Disopyramide and Pitolisant. Somnolence [MG42] [46]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Disopyramide and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [46]
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Disopyramide and Adenosine. Supraventricular tachyarrhythmia [BC81] [115]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Disopyramide caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [116]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Disopyramide and Lenvatinib. Thyroid cancer [2D10] [46]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Disopyramide and Cabozantinib. Thyroid cancer [2D10] [46]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Disopyramide and Papaverine. Tonus and reflex abnormality [MB47] [117]
Tizanidine DMR2IQ4 Major Increased risk of prolong QT interval by the combination of Disopyramide and Tizanidine. Tonus and reflex abnormality [MB47] [46]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Disopyramide and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [112]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Disopyramide and Tacrolimus. Transplant rejection [NE84] [46]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Disopyramide and Tolbutamide. Type 2 diabetes mellitus [5A11] [50]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Disopyramide and Chlorpropamide. Type 2 diabetes mellitus [5A11] [50]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Disopyramide and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [50]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Disopyramide and Insulin degludec. Type-1/2 diabete [5A10-5A11] [50]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Disopyramide and Atropine. Unspecific substance harmful effect [NE6Z] [53]
Astemizole DM2HN6Q Major Increased risk of prolong QT interval by the combination of Disopyramide and Astemizole. Vasomotor/allergic rhinitis [CA08] [46]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Disopyramide and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [53]
Triprolidine DM7SWIA Moderate Additive anticholinergic effects by the combination of Disopyramide and Triprolidine. Vasomotor/allergic rhinitis [CA08] [53]
Triamcinolone DM98IXF Moderate Increased risk of ventricular arrhythmias by the combination of Disopyramide and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [52]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Disopyramide and Methdilazine. Vasomotor/allergic rhinitis [CA08] [53]
Clemastine DMBZWQL Moderate Additive anticholinergic effects by the combination of Disopyramide and Clemastine. Vasomotor/allergic rhinitis [CA08] [53]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Disopyramide and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [53]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Disopyramide and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [46]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Disopyramide and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [53]
Dexbrompheniramine DMKVWGE Moderate Additive anticholinergic effects by the combination of Disopyramide and Dexbrompheniramine. Vasomotor/allergic rhinitis [CA08] [53]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Disopyramide and Acrivastine. Vasomotor/allergic rhinitis [CA08] [53]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Disopyramide and Azatadine. Vasomotor/allergic rhinitis [CA08] [53]
⏷ Show the Full List of 363 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 33 E00261 19116 Colorant
Erythrosine sodium anhydrous E00324 27872 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Food blue 1 aluminum lake E00512 11979396 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric oxide black E00522 16211978 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Gelatin E00630 Not Available Other agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sorbitan monolaurate E00508 11046239 Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Ethyl cellulose E00699 Not Available Coating agent; Microencapsulating agent; Binding agent; Diluent; Viscosity-controlling agent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
Shellac E00695 Not Available Coating agent; Film/membrane-forming agent; Microencapsulating agent; Modified-release agent
⏷ Show the Full List of 29 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Disopyramide 100 mg capsule 100 mg Oral Capsule Oral
Disopyramide 150 mg capsule 150 mg Oral Capsule Oral
Disopyramide 150 mg capsule 150 mg 12 HR Extended Release Oral Capsule Oral
Disopyramide Phosphate eq 100mg base capsule eq 100mg base Capsule Oral
Disopyramide Phosphate eq 150mg base capsule eq 150mg base Capsule Oral
Disopyramide 100 mg capsule 100 mg 12 HR Extended Release Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7167).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070101.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 BDDCS applied to over 900 drugs
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
9 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
10 Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica. 2001 Feb;31(2):73-83.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
21 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
22 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
23 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
24 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
25 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
26 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
27 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
28 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
29 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
30 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
31 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
32 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
33 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
34 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
35 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
36 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
37 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
38 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
39 Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
40 Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
41 Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
42 Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
43 From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.
44 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
45 Cerner Multum, Inc. "Australian Product Information.".
46 Canadian Pharmacists Association.
47 Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985): 424-8. [PMID: 4043097]
48 James MA, Papouchado M, Vann Jones J "Combined therapy with disopyramide and amiodarone: a report of 11 cases." Int J Cardiol 13 (1986): 248-52. [PMID: 3793283]
49 Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
50 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
51 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
52 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
53 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
54 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
55 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
56 Hollingshead LM, Faulds D, Fitton A "Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris." Drugs 44 (1992): 835-57. [PMID: 1280569]
57 Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
58 Product Information. Norpace (disopyramide). Searle, Skokie, IL.
59 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
60 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
61 Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
62 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
63 Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
64 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
65 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
66 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
67 Multum Information Services, Inc. Expert Review Panel.
68 Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U "Iohexol contrast medium induces QT prolongation in amiodarone patients." Br J Clin Pharmacol 58 (2004): 96-98. [PMID: 15206999]
69 Kapil RP, Axelson JE, Mansfield IL, et al. "Disopyramide pharmacokinetics and metabolism: effect of inducers." Br J Clin Pharmacol 24 (1987): 781-91. [PMID: 3440098]
70 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
71 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
72 Ellrodt G, Singh BN "Adverse effects of disopyramide (norpace): toxic interactions with other antiarrhythmic agents." Heart Lung 9 (1980): 469-74. [PMID: 6901519]
73 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
74 Olsen H, Bredesen JE, Lunde PK "Effect of ethanol intake on disopyramide elimination by healthy volunteers." Eur J Clin Pharmacol 25 (1983): 103-5. [PMID: 6617710]
75 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
76 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
77 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
78 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
79 Aitio ML, Mansury L, Tala E, et al "The effect of enzyme induction on the metabolism of disopyramide in man." Br J Clin Pharmacol 11 (1981): 279-85. [PMID: 7213529]
80 Bonde J, Bodtker S, Angelo HR, Svedsen TL, Kampmann JP "Atenolol inhibits the elimination of disopyramide." Eur J Clin Pharmacol 28 (1985): 41-3. [PMID: 3987784]
81 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
82 Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
83 Product Information. Nizoral (ketoconazole). Janssen Pharmaceutica, Titusville, NJ. (1992):.
84 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
85 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
86 Aitio ML, Mansury L, Tala E, Haataja M, Aitio A "The effect of enzyme induction on the metabolism of disopyramide in man." Br J Clin Pharmacol 11 (1981): 279-85. [PMID: 7213529]
87 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
88 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
89 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
90 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
91 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
92 Abernethy DR, Egan JM, Dickinson TH, Carrum G "Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans." J Pharmacol Exp Ther 244 (1988): 994-9. [PMID: 3252045]
93 Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
94 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
95 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
96 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
97 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
98 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
99 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
100 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
101 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
102 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
103 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
104 Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
105 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
106 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
107 Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
108 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
109 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
110 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
111 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
112 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
113 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
114 Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
115 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
116 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
117 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]